Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.
Blinatumomab, a bispecific T-cell engager (BiTE), nearly doubled overall survival (OS) and complete remission (CR) rate vs standard chemotherapy in patients with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) in the phase III TOWER trial.
A large study presented at the 21st Congress of European Haematology Association (EHA) provides further evidence for the feasibility and safety of stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukaemia (CML) who have achieved a deep molecular response (MR).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.